SIRAKOSS has developed MaxSi™, a synthetic bone graft substitute, and is in pursuit of funding to support regulatory clearance and clinical trials for the product, to support global market introduction.
The company will initially focus upon applications in the spinal market, to be followed by trauma, maxillofacial, etc.
MaxSi incorporates a unique chemical composition and physical properties that, in specific combination, have been shown to deliver clear benefits in bone fusion correlating to early recovery for the patient and cost benefits for healthcare providers.
Novel synthetic bone graft in running for national innovation award. University of Aberdeen, 12/2/11.